Pittsburgh Business Times- UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
RxAnte will continue to operate as an independent company, and the investment from UPMC Enterprises will allow it to expand its offerings for Medicare, Medicaid and commercial populations, and to extend its predictive models and workflow tools to high-cost specialty drugs.
Recent Posts
How to Build A Race Car…Or A Really Good Agile Program
Building a great agile program is hard and an ever-evolving activity. It’s complex and requires system-level thinking with an intuitive understanding of engineering tradeoffs, bottlenecks, and flow dynamics. Much like a racecar driver, one cannot expect a driver to understand and be consciously aware of every detail happening in his car while he is racing down the track.
Read More →
Report calls Pittsburgh top emerging life sciences cluster in U.S.
Pittsburgh is the top emerging life sciences cluster in the United States, according to a new report from commercial real estate firm CBRE.
Read More →